By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

It is incumbent not only on people to have the willingness to learn, but also on pharmaceutical and scientific industries to ...

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

Reports Q3 revenue $60.3M vs. $44.75M last yearInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...

Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

The Connecticut Supreme Court has cleared the way for a lawsuit against a fertility doctor accused of secretly using his own ...